Sign In
Buy AVDL
$21.64
+0 (+0%)
At Close: May 08, 2026
Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting
04:47pm, Wednesday, 03'rd Dec 2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting
04:05pm, Monday, 01'st Dec 2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Handelsbanken Fonder AB Takes Position in Avadel Pharmaceuticals PLC. $AVDL
05:18am, Monday, 01'st Dec 2025
Handelsbanken Fonder AB purchased a new position in shares of Avadel Pharmaceuticals PLC. (NASDAQ: AVDL) in the second quarter, according to the company in its most recent filing with the Securities a
Halper Sadeh LLC Encourages SEMR, AVDL, CADE, DENN Shareholders to Contact the Firm to Discuss Their Rights
06:15pm, Wednesday, 19'th Nov 2025
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Alkermes raises offer for Avadel after Lundbeck bid
06:08am, Wednesday, 19'th Nov 2025
Alkermes said on Wednesday it has sweetened its offer to buy Avadel Pharmaceuticals , beating a rival bid from Denmark's Lundbeck and valuing the sleep disorder drugmaker at up to $2.37 billion.
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
06:00am, Wednesday, 19'th Nov 2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO
Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal
11:41am, Tuesday, 18'th Nov 2025
AVDL's board calls Lundbeck's higher $23-per-share bid superior to its Alkermes deal, triggering a critical five-day response window.
Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”
05:45am, Monday, 17'th Nov 2025
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014
Market Today: Data Delays, CEO Shifts, M&A and Deals
05:35pm, Friday, 14'th Nov 2025
Guru Stock PicksSteven Cohen has made the following transactions:Reduce in FLR by 57.92%Sold out in TATTAdd in GDEN by 26.14%New position in KEXValueAct Capital
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal
11:37am, Friday, 14'th Nov 2025
Avadel Pharmaceuticals plc (NASDAQ: AVDL) on Friday received an unsolicited proposal from H. Lundbeck A/S for up to $23.00 per ordinary share.
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
09:40am, Friday, 14'th Nov 2025
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid
09:18am, Friday, 14'th Nov 2025
A new bidding war could kick off in biotech with Avadel Pharmaceuticals at the center and initial acquirer Alkermes facing off with Lundbeck.
Alkermes reviewing options after Lundbeck makes unsolicited bid for Avadel
08:17am, Friday, 14'th Nov 2025
Alkermes said on Friday it is reviewing its options with advisers after Avadel Pharmaceuticals disclosed it had received an unsolicited takeover proposal from Danish pharmaceutical company Lundbeck.
Avadel Receives Unsolicited Proposal from Lundbeck
05:45am, Friday, 14'th Nov 2025
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FR
FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc
11:10am, Wednesday, 05'th Nov 2025
U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER
